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Background: Ginsenosides are the major components of Panax ginseng Meyer, an herbal medicine used
for the treatment of various diseases. Different ginsenosides contribute to the biological properties of
ginseng, such as antimicrobial, anticancer, and immunomodulatory properties. In this study, we inves-
tigated the antiviral effects of 15 ginsenosides and compound K on gammaherpesvirus.
Methods: The antiviral activity of ginsenosides was examined using the plaque-forming assay and by
analyzing the expression of the lytic gene.
Results: 20(R)-Ginsenoside Rh2 inhibited the replication and proliferation of murine gammaherpesvirus
68 (MHV-68), and its half-maximal inhibitory concentration (IC50) against MHV-68 was estimated to be
2.77 mM. In addition, 20(R)-ginsenoside Rh2 inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-
induced lytic replication of human gammaherpesvirus in the Kaposi’s sarcoma-associated herpesvirus
(KSHV)-positive cell line BC3.
Conclusion: Our results indicate that 20(R)-ginsenoside Rh2 can inhibit the replication of mouse and
human gammaherpesviruses, and thus, has the potential to treat gammaherpesvirus infection.
Copyright  2016, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ginseng, the root of Panax ginseng Meyer (Araliaceae), is one of
the most popular herbal medicines that has been traditionally used
in East Asian countries, including Japan, China, and Korea [1].
Ginseng has pharmacological effects on immune function, cancer,
neurodegenerative disorders, inﬂammation, and viral diseases [2e
7].
Ginseng contains various physiologically active compounds
such as ginsenosides, polysaccharides, polyacetylenes, phytos-
terols, and essential oils [8]. Ginsenosides are triterpenoid glyco-
sides containing dammarane and are generally divided into two
groups: the protopanaxadiol ginsenosides (e.g., Rb1, Rb2, Rb3, Rc,
Rd, Rg3, and Rh2) and protopanaxatriol ginsenosides (e.g., Re, Rf,
Rg1, Rg2, and Rh1) [7,9]. Ginsenosides and their enzymatic or heat-
processed metabolites, such as compound K, are the major active
components of ginseng that contribute to its pharmacological ac-
tivities [7,10e12].
Human gammaherpesviruses such as the EpsteineBarr virus
(EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) are
oncoviruses, distinguished by their ability to establish a lifelongg-Ang University, 84 Heukseok-ro
ht  2016, The Korean Society of G
d/4.0/).
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0.1016/j.jgr.2016.08.010persistent infection in lymphocytes and to induce latent and lytic
replication [13,14]. This characteristic life cycle of gamma-
herpesviruses, especially latency and persistent infection, is highly
associated with the development of various cancers [13,15]. KSHV,
also known as human herpesvirus 8, is associated with Kaposi’s
sarcoma, multicentric Castleman’s disease, and primary effusion
lymphoma [16e18]. EBV, or human herpesvirus 4, causes Burkitt’s
lymphoma, nasopharyngeal carcinoma, Hodgkin’s disease, and
some gastric cancers [19,20]. In a few cases, lytic replication is also
related to the development of malignancies, AIDS-associated
epidemic Kaposi’s sarcoma caused by KSHV, and hemophagocytic
lymphohistiocytosis caused by EBV [21,22]. Hence, regulation of the
life cycle of a gammaherpesvirus through effective antiviral agents
is very important for the treatment of viral disorders.
Owing to the absence of an appropriate experimental model for
human gammaherpesviruses, studies on KSHV and EBV are limited
[23]. The murine gammaherpesvirus 68 (MHV-68), a member of
the subfamily of Gammaherpesvirinae fromwild rodents, has been
developed as an experimental model for these studies [24]. Similar
to other human gammaherpesviruses, MHV-68 exhibits two
distinct phases of life cycle and has genetic similarity with KSHV, Dongjak-gu, Seoul 06974, South Korea.
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
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Table 1
The list of primers used for qRT-PCR
Primer Direction Sequence (50 to 30)
MHV-68 RTA Sense GGCCGCAGACATTTAATGAC
Antisense GCCTCAACTTCTCTGGATATGCC
MHV-68 ORF56 Sense GTAACTCGAGACTGAAACCTCGCAGAGGTCC
Antisense CCGAAGCTTGCACGGTGCAATGTGTCACAG
KSHV RTA Sense CCCTGAGCCAGTTTGTCATT
Antisense ATGGGTTAAAGGGGATGATG






KSHV ¼ Kaposi’s sarcoma-associated herpesvirus; MHV ¼ murine gamma-
herpesvirus; qRT-PCR ¼ quantitative real-time PCR; RTA ¼ replication and tran-
scription activator; Actb ¼ actin, beta; GAPDH ¼ Glyceraldehyde 3-phosphate
dehydrogenase.
J Ginseng Res 2016;-:1e72and EBV [24,25]. Thus, MHV-68 is regarded as a substitute for the
human gammaherpesvirus and has been widely used for in vitro
and in vivo studies on gammaherpesviruses. In this study, we aimed
to investigate the antiviral effects of 15 ginsenosides and com-
pound K on gammaherpesviruses, and our results showed that
20(R)-ginsenoside Rh2 had an inhibitory effect on lytic replication
and viral proliferation of the gammaherpesvirus MHV-68.
Furthermore, we identiﬁed the antiviral activity of 20(R)-ginseno-
side Rh2 on human gammaherpesvirus by using KSHV-positive cell
lines.
2. Materials and methods
2.1. Cell lines and viruses
Vero (green monkey kidney cell) cells were cultured in Dul-
becco’s modiﬁed Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (Welgene, Seoul, Korea), 100 U/mL penicillin,
and 100 mg/mL streptomycin. The mouse ﬁbroblast cell line NIH-
3T3 was cultured in DMEM with 10% bovine calf serum (Gibco,
Grand Island, NY, USA). KSHV-positive B cell lymphoma (BC-3) cells
were cultured in RPMI1640 supplemented with 20% fetal bovine
serum, 100 U/mL penicillin, and 100 mg/mL streptomycin. The cells
were cultured at 37C in a humidiﬁed 5% CO2 atmosphere. MHV-68
was originally obtained from American Type Culture Collection
(VR1465). Working virus stocks were grown in Vero cells in normal
growth media at a multiplicity of infection (MOI) of 0.05 plaque-
forming unit (PFU)/cell.
2.2. Chemicals
Ginsenosides Rb1, Rb2, Rb3, Rc, Re, Rf, Rg1, 20(R)- and 20(S)-
Rg2, 20(R)- and 20(S)-Rg3, 20(S)-Rh1, 20(R)- and 20(S)-Rh2, Rp1,
and compound K were purchased from Ambo Institute (Daejeon,
Korea), and 12-O-tetradecanoylphorbol-13-acetate (TPA) for virus
reactivation was from Sigma-Aldrich (St. Louis, MO, USA). The
working stock solutions were prepared by dissolving the com-
pounds in dimethyl sulfoxide (DMSO) and diluted to the appro-
priate concentrations in culture medium.
2.3. Cytotoxicity assays
Cytotoxicity was determined by measuring the mitochondrial-
dependent reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT) to formazan by viable cells.
NIH-3T3 cells were seeded at a density of 2  103 cells/100 mL per
well in 96-well plates, incubated for 6 h and treated with 0.5 mL of
ginsenosides and compound K. After 72 h, 10 mL MTT (5 mg/mL
solution; Sigma Aldrich) was added to the culture, followed by
incubation for 6 h at 37C in a CO2 incubator. Isopropanol with
hydrochloric acid (0.04N,100 mL) was added to eachwell to dissolve
the formazan crystals. Estimation of MTT reduction to formazan by
viable cells was quantiﬁed bymeasuring the absorbance at 540 nm,
and cytotoxicity was represented as the percentage of cell viability
rate, calculated as {[(sample OD e blank OD)/(DMSO OD e blank
OD)]  100}. Where OD ¼ optical density.
2.4. Ginsenoside treatment and virus infection
For ginsenoside treatment, NIH-3T3 cells were plated onto 24-
well plates at 2  104 cells/well and stabilized for 6 h. After 6 h
stabilization, cells were treated with each ginsenoside at the
appropriate concentration and incubated for 24 h. Cells were then
rinsed with warm phosphate-buffered saline (PBS) twice, and
inoculated with MHV-68 at an MOI of 0.1 pfu/cell or 0.05 pfu/cellPlease cite this article in press as: Kang S, et al., Antiviral activity of 20
Ginseng Research (2016), http://dx.doi.org/10.1016/j.jgr.2016.08.010for 90min at 37C, rocking every 15min. After inoculation, NIH-3T3
cells were washed with warm PBS and cultured with ginsenoside-
containing complete culture media. After 72 h culture, cells, and
supernatants were used for further experiments.
2.5. Cell-based antiviral assays
The number of PFUs in virus stocks and virus-infected samples
were titrated using the plaque-forming assay with Vero cells. Vero
cells were plated onto 12-well plates at 2.5  104 cells/well and
incubated for 24 h. Serial 10-fold dilutions of the virus stock or
appropriately diluted samples were added to Vero cells at a volume
of 400 mL and allowed to inoculate for 90min at 37C, rocking every
15min. After inoculation, Vero cells werewashed once inwarm PBS
and overlaid with complete DMEM containing 0.6%methylcellulose
(Sigma-Aldrich). After 7 d culture, the cells were ﬁxed and stained
with 2% crystal violet in 20% ethanol for 8 h, and plaques were
counted to determine the viral titers.
2.6. Real-time quantitative polymerase chain reaction
Total RNA and genomic DNA were extracted by using RNAiso
plus (Takara Bio Inc., Otsu, Shiga, Japan) according to manufac-
turer’s instructions. The expressions of the mRNA and genomic
DNA of the genes of interest were analyzed by real-time quantita-
tive polymerase chain reaction (qRT-PCR) with SYBR green (Enzy-
nomics, Daejeon, Korea) as previously described [26]. MHV-68
replication and transcription activator (RTA)- and MHV-68 ORF56-
speciﬁc primers were used to measure MHV-68 lytic gene expres-
sion and genomic DNA ampliﬁcation. KSHV ORF57 locus- and RTA-
speciﬁc primers were used to quantitate the KSHV viral load and
lytic gene expression, as previously reported. All gene expressions
were normalized using Actb (actin, beta; mouse) or GAPDH (glyc-
eraldehyde 3-phosphate dehydrogenase; human) and the primer
sequences are listed in Table 1. qRT-PCR reactions were performed
using CFX Connect Real-Time PCR Detection System (Bio-Rad,
Hercules, CA, USA).
2.7. Western blot analysis
For western blot analysis, total protein samples were extracted
using the RIPA Lysis and Extraction Buffer (Thermo Fisher Scientiﬁc,
Rockford, IL, USA) and further experiments were performed as
previously described [27]. Rabbit polyclonal anti-ORF45 and anti-
M9 antibodies were kindly provided by Dr. Moon Jung Song (Ko-
rea University, Seoul, Korea) and used at a dilution of 1:1,000. Other(R)-ginsenoside Rh2 against murine gammaherpesvirus, Journal of
S. Kang et al / Antiviral effect of 20(R)-ginsenoside Rh2 3primary antibodies were diluted as follows: anti-K8a (Santa Cruz
Biotechnology, Dallas, TX, USA) 1:200, and anti-b-tubulin (Cell
Signaling, Beverly, MA, USA) 1:2,000. Horseradish peroxidase-
conjugated antirabbit immunoglobulin G (Bio-Rad) and horse-
radish peroxidase-conjugated antimouse immunoglobulin G (Cell
Signaling) were used as secondary antibodies.2.8. Plaque reduction assays for 20(R)-ginsenoside Rh2
To determine the half-maximal inhibitory concentration (IC50)
of 20(R)-ginsenoside Rh2 against MHV-68, we performed the pla-
que reduction assay as previously described [23]. Brieﬂy, Vero cells
were seeded at 2.5  104 cells/well in 12-well plates. After 24 h, the
cells were incubated with MHV-68 (100 pfu/well) for 90 min and
the overlay media was added upon removal of the virus inoculum.
20(R)-ginsenoside Rh2 was diluted at various concentrations into
the normal growth media for pretreatment (24 h before virus
inoculation) or the overlay media for posttreatment and added into
the cells. After 7 days culture, the cells were ﬁxed and stained with
2% crystal violet in 20% ethanol for 8 h. The plaques were counted,
and the IC50 value was determined using the Prism 5 (GraphPad
Software Inc., San Diego, CA, USA).2.9. Statistical analysis
All data were expressed as mean  standard deviation, and the
two-tailed, unpaired Student t test was applied using Microsoft
Excel 2013 (Redmond,WA, USA). A value of p< 0.05was considered
statistically signiﬁcant.3. Results
3.1. Cytotoxic effects of ginsenosides and compound K
Prior to determining the antiviral activity of 15 ginsenosides and
compound K, MTT assays were performed to test their cytotoxic
effects at 100 mM in NIH-3T3 cells. Most ginsenosides did not affect
the cell viability, while ginsenosides 20(S)-Rg3, 20(S)-Rh2, and Rp1
and compound K showed cytotoxicity at 100 mM (Fig. 1). Therefore,
we did not include these cytotoxic compounds in further
experiments.Fig. 1. Cytotoxicity of ginsenosides and compound K. Cell viability was expressed as
the percent ratio of ginsenoside or compound K treatment normalized over 0.5%
DMSO control value. The data are representative of three experiments with similar
results. ** p < 0.01; *** p < 0.001. DMSO, dimethyl sulfoxide.
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To evaluate the antiviral activity of ginsenosides, we measured
the inhibition of plaque formation in NIH-3T3 cells infected with
MHV-68 at an MOI of 0.1 pfu/cell by using 12 ginsenosides at 100
mM. Our results showed that ginsenosides Rb3, Rc, 20(R)-Rg3, and
20(R)-Rh2 reduced plaque formation, which indicated a decrease in
viral proliferation (Fig. 2A). In addition, the level of MHV-68 RTA, an
immediate-early lytic gene required for the initiation of viral
replication, decreased following treatment with ginsenosides Rb3,
Rf, Rg1, 20(R)-Rg2, 20(R)-Rg3, and 20(R)-Rh2 (Fig. 2B). In particular,
20(R)-ginsenoside Rh2 signiﬁcantly inhibited viral proliferation
and lytic gene expression, which indicated that 20(R)-ginsenoside
Rh2 had a marked antiviral activity against MHV-68.
3.3. 20(R)-ginsenoside Rh2 inhibits viral replication
To conﬁrm the antiviral effect of 20(R)-ginsenoside Rh2 against
MHV-68, we treated NIH-3T3 cells with 100 mM of 20(R)-ginse-
noside Rh2 before and after infection with the MHV-68 virus at an
MOI of 0.05 pfu/cell, and we examined the viral replication at 72 h
after infection. The infected cells treated with DMSO were used as
negative controls. Treatment with 20(R)-ginsenoside Rh2 sup-
pressed the expression of RTAmRNA at an MOI 0.05 pfu/cell; these
results were consistent with those observedwith infectionwith the
MHV-68 virus at an MOI of 0.01 pfu/cell. In addition, treatment
with 20(R)-ginsenoside Rh2 inhibited the expression of the viral
ORF56 gene associated with the regulation of viral DNA synthesis
(Figs. 3A and 3B). Furthermore, we examined viral protein ex-
pressions. Treatment with 20(R)-ginsenoside Rh2 treatment had
inhibitory effects on the expressions of late genes such as ORF45
(viral tegument protein) and M9 (also known as ORF65, small
capsid protein) (Fig. 3C). These results conﬁrmed the antiviral ac-
tivity of 20(R)-ginsenoside Rh2 against MHV-68.
3.4. Antiviral efﬁcacy of 20(R)-ginsenoside Rh2
We performed plaque reduction assays using 20(R)-ginsenoside
Rh2 at a concentration ranging from 0.098 mM to 100 mM, and we
calculated the IC50 of 20(R)-ginsenoside Rh2. The IC50 of 20(R)-
ginsenoside Rh2 against MHV-68 was estimated to be 2.77 mM
(Fig. 4).
3.5. 20(R)-ginsenoside Rh2 inhibits virus replication following virus
entry
To examine the stage of viral replication at which 20(R)-ginse-
noside Rh2 exerts its activity, we treated Vero cells with 20(R)-
ginsenoside Rh2 before virus infection (pretreatment group), after
infection (posttreatment group), or before and after infection
(pretreatment and posttreatment group) (Fig. 5A). Then, we per-
formed plaque formation assays to measure viral replication, and
the expressions of RTA and ORF56 were analyzed using qRT-PCR.
Pretreatment with 20(R)-ginsenoside Rh2 had no effects on the
inhibition of plaque formation, while posttreatment and pretreat-
ment and posttreatment groups inhibited viral proliferation
(Figs. 5B and 5C). Similar to the results of the plaque formation
assay, the results of analysis of the expressions of RTA and ORF56
showed that the expressions of RTA and ORF56 were not repressed
in the group pretreated with 20(R)-ginsenoside Rh2 but were
repressed in the posttreatment and preretreatment and post-
treatment groups (Figs. 5D and 5E). Taken together, these results
suggest that 20(R)-ginsenoside Rh2 does not block the entry of the
virus into the cells but inhibits the replication of MHV-68 after
entry into the cells.(R)-ginsenoside Rh2 against murine gammaherpesvirus, Journal of
Fig. 3. Effects of 20(R)-ginsenoside Rh2 (100 mM) on MHV-68 replication determined by different measurements. (A) The levels of viral transcript RTA. (B) Viral genome ORF56
ampliﬁcation. (C) Viral lytic protein expression. Uninfected (mock) and DMSO-treated infected samples were used as control. Relative values were calculated against DMSO-treated
infected control. The data are representative of three experiments with similar results. *** p < 0.001.
Fig. 2. Effect of ginsenosides. (A) Effect on the levels of virus production. (B) Effect on viral transcript RTA. All ginsenosides were used at a concentration of 100 mM, and uninfected
(mock) and DMSO-treated infected samples were used as control. Virus replication levels were represented as a relative value compared with that obtained using a DMSO control.
The data are representative of three experiments with similar results. * p < 0.05; ** p < 0.01; *** p < 0.001. ND, not detected; RTA, replication and transcription activator.
J Ginseng Res 2016;-:1e743.6. Antiviral activity of 20(R)-ginsenoside Rh2 against KSHV
MHV-68 is genetically related to human gammaherpesviruses
such as KSHV and EBV, and its life cycle is similar to that of KSHV
and EBV. Thus, we examined the antiviral effects of 20(R)-ginse-
noside Rh2 against KSHV. To evaluate the effects of 20(R)-Fig. 4. The antiviral efﬁcacy (IC50) of 20(R)-ginsenoside Rh2. Plaque formation was
described as relative data compared with those obtained using DMSO-treated infected
control. IC50 represents the concentration of 20(R)-ginsenoside Rh2 required for 50%
inhibition of MHV-68 replication. The data are representative of three experiments
with similar results.
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line latently infected with KSHV and analyzed lytic reactivation
after TPA induction. Compared with untreated TPA-induced BC-3
cells, those treated with 20(R)-ginsenoside Rh2 induced a signiﬁ-
cant dose-dependent decrease in the protein expression of the late
lytic gene KSHV K8a (Figs. 6A and 6B). In addition, KSHV RTAmRNA
and viral DNA ampliﬁcation levels were inhibited by 20(R)-ginse-
noside Rh2 treatment (Figs. 6C and 6D). Taken together, our results
indicate that 20(R)-ginsenoside Rh2 possesses effective antiviral
activity against human gammaherpesviruses such as KSHV, as well
as the murine gammaherpesvirus MHV-68.4. Discussion
Antiviral activities of several ginsenosides have been reported in
previous studies. Protopanaxatriol-type ginsenosides such as gin-
senoside Re, Rf, and Rg2 protect the host from rhinovirus 3 and
coxsackievirus infections [9], while ginsenoside Rb1 suppresses
viral infection and proliferation of various viruses, such as hepatitis
A virus, norovirus, and herpes simplex virus (HSV) [28e30]. In
addition, ginsenoside Rg3 markedly inhibits the secretion of hep-
atitis B surface antigen, hepatitis B envelope antigen, and viral
particles in hepatitis B virus-infected HepG2.2.15 cells by down-
regulating tumor necrosis factor receptor-associated factor 6/
transforming growth factor b activated kinase-1 and the mitogen-(R)-ginsenoside Rh2 against murine gammaherpesvirus, Journal of
Fig. 5. Stage of antiviral activity against MHV-68 by 20(R)-ginsenoside Rh2. (A) A schematic diagram describing the experimental scheme for measuring the stage at which
20(R)-ginsenoside Rh2 exerts its effects. (B) A representative picture of plaque reduction assays. (C) Relative plaque formations (%) compared with DMSO-treated lytic sample
were calculated. (D) Changes in viral transcript RTA. (E) Changes in genome ORF56 replication. The data are representative of three experiments with similar results. * p < 0.05;
*** p < 0.001.
S. Kang et al / Antiviral effect of 20(R)-ginsenoside Rh2 5activated protein kinase signaling pathway [31]. However, to date,
no study has reported the antiviral activity of ginsenosides against
gammaherpesviruses, and thus, we assessed the antiviral activities
of 15 ginsenosides and compound K using MHV-68, a murine
model similar to human gammaherpesviruses. We found that
ginsenosides Rb3, Rc, 20(R)-Rg2, 20(S)-Rg2, 20(R)-Rg3, and 20(R)-
Rh2 exerted antiviral activities by reducing plaque formation and
mRNA expression of RTA. In particular, 20(R)-ginsenoside Rh2
showed the most signiﬁcant antiviral effect against MHV-68.
Natural ginseng contains small amounts of ginsenoside Rh2,
which is about 0.01% of the ginseng extract [32e34]. However,
some naturally abundant ginsenosides such as Rg3, Rb1, Rb2, and
Rc could also be metabolized into Rh2 by the intestinal bacteria
after absorption, which suggests that the level of ginsenoside
Rh2 after ingestion of the ginseng extract would be higher thanPlease cite this article in press as: Kang S, et al., Antiviral activity of 20
Ginseng Research (2016), http://dx.doi.org/10.1016/j.jgr.2016.08.010expected [34,35]. In addition, the antiviral activities of ginsenosides
Rg3 and Rb1 might be partly derived from ginsenoside Rh2, which
is intestinally converted from Rg3 and Rb1.
Recent studies have shown that ginsenoside Rh2 has two ste-
reoisomers, 20(R)-ginsenoside and 20(S)-ginsenoside, and they
exert different pharmacological effects [32,35,36]. Typically, the
20(S)-ginsenoside Rh2 possesses strong cytotoxic activities, and
thus, it has been considered as an anticancer agent. Previous
studies showed that 20(S)-ginsenoside Rh2 had cytotoxic effects on
various tumor cell lines such as breast cancer, leukemia, lung
cancer, and cervical carcinoma and had an IC50 as low as 22 mM
against lymphocytic leukemia cells. However, treatment with
20(R)-ginsenoside Rh2 at concentrations up to 100 mM had no
signiﬁcant cytotoxic effects, which is consistent with the results of
our cytotoxicity test using the ﬁbroblast cell line NIH-3T3 [35,37].(R)-ginsenoside Rh2 against murine gammaherpesvirus, Journal of
Fig. 6. Effects of 20(R)-ginsenoside Rh2 on KSHV reactivation were determined by different measurements. (A, B) The levels of a viral lytic protein K8a. (C) KSHV RTA mRNA
expression. (D) Viral genome ampliﬁcation. * p < 0.05; ** p < 0.01; *** p < 0.001. DMSO, dimethyl sulfoxide; KSHV, Kaposi’s sarcoma-associated herpesvirus; TPA, 12-O-tetra-
decanoylphorbol-13-acetate.
J Ginseng Res 2016;-:1e7620(R)-ginsenoside Rh2 exerts anti-inﬂammatory effects in
lipopolysaccharide-activated macrophages and naïve keratinocytes
through the suppression of reactive oxygen species and inﬂam-
matory mediators [32,38,39]. Relatively fewer functions of 20(R)-
ginsenoside Rh2 have been identiﬁed thus far; therefore, it is
important to reveal novel antiviral effects of 20(R)-ginsenoside Rh2
on MHV-68.
MHV-68 is a surrogate model for the study of human KSHV
infections, and thus, we examined the antiviral effects of 20(R)-
ginsenoside Rh2 in a KSHV model [24]. Similar to the results
observed in the MHV-68 study, results of the treatment of KSHV-
infected cells with TPA showed that 20(R)-ginsenoside Rh2
inhibited virus reactivation by inhibiting plaque formation,
expression of viral transcript, and genome replication. RTA is
necessary and sufﬁcient for the reactivation of KSHV, resulting in
the switch from latency to lytic replication, and nuclear factor
kappa B (NF-kB) pathways negatively regulate RTA and repress
lytic viral replication [40]. Qi et al [41] reported that 20(R)-gin-
senoside Rh2 increased the phosphorylation of inhibitor of kappa
B (IkB) and activated NF-kB; therefore it is highly likely that 20(R)-
ginsenoside Rh2 might activate NF-kB via phosphorylation of IkB,
repress RTA, and inhibit lytic replication in the KSHV model.
In addition to KSHV, we anticipate that 20(R)-ginsenoside Rh2
might have antiviral effects on other types of human herpesviruses
such as HSV-1, HSV-2, varicella-zoster virus, and human cyto-
megalovirus, or other classes of viruses whose life cycles are
entirely different from those of gammaherpesviruses. Furthermore,
the antiviral activities of ginsenosides Rb3, Rf, Rg1, 20(R)-Rg2, and
20(R)-Rg3 need to be examined more thoroughly.Please cite this article in press as: Kang S, et al., Antiviral activity of 20
Ginseng Research (2016), http://dx.doi.org/10.1016/j.jgr.2016.08.010Conﬂict of interest
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